Milestone Pharmaceuticals (MIST) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Oncolytics Biotech (ONCY) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 65.0% versus a loss of 84.5%. Over five years, ONCY leads with a -80.7% price change compared with -93.8% for MIST. Oncolytics Biotech is the larger company by market cap ($47.7 million vs $46.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIST | ONCY |
|---|---|---|
| Share price | $0.3711 | $0.3501 |
| Market cap | $46.20M | $47.66M |
| 1-day change | -7.06% | -10.37% |
| YTD return | -81.63% | -59.76% |
| 1-year return | -84.54% | -64.99% |
| 5-year return | -93.85% | -80.66% |
| EPS (TTM) | $-0.74 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-63.06M | $-28.76M |
| 52-week high | $3.06 | $1.30 |
| 52-week low | $0.362 | $0.33 |
| Distance from 52-week high | -87.87% | -73.07% |
| Analyst consensus | none | buy |
| Avg. price target upside | +1479.09% | +1085.38% |
| Average volume | 1.53M | 1.17M |
| Shares outstanding | 124.50M | 136.14M |
| Employees | 38 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ONCY has outperformed MIST by 19.5 percentage points over the past year.
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
MIST vs ONCY FAQ
Which is bigger, Milestone Pharmaceuticals or Oncolytics Biotech?
Oncolytics Biotech (ONCY) is larger, with a market capitalization of $47.66M compared with $46.20M for Milestone Pharmaceuticals (MIST).
Which stock has performed better over the past year, MIST or ONCY?
ONCY returned -64.99% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Milestone Pharmaceuticals and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.